Phapros Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Phapros Tbk. trades at Rp298 (market cap 250.32B, 116.6K 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Phapros Tbk. is far larger — about 2.4× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| PEHA | SCPI | |
|---|---|---|
Market Cap | 250.32B | 104.4B |
Volume | 116.6K | — |
Lot | 1.17K | — |
Turnover | 34.22M | — |
Average Price | 293.45 | — |
Value | 34.22M | — |
Indicative Equilibrium Price | 300 | — |
Indicative Equilibrium Volume | 7 | — |
Trailing returns across standard periods
Latest headlines on both assets
PT Phapros Tbk was established under the name of N.V. Pharmaceutical Processing Industries, in short N.V. Phapros, based on Notarial Deed No 54 of Tan A Sioe dated 21 June 1954, which later became PT Pharmaceutical Processing Industries, in short PT Phapros based on Notarial Deed No.43 of E. Pondaag, replacing R.M. Soerojo, dated 5 September 1995, which finally became PT Phapros based on Notarial Deed No. 48 of Prof. Dr. Liliana Tedjosaputro, S.H., M.H., MM., dated 12 April 2006. The Company’s immediate and ultimate parent entity is PT Rajawali Nusantara Indonesia, incorporatedand domiciled in Indonesia.
Read more on PEHA →PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →